In its largest-ever transaction, BioNTech has agreed to purchase UK artificial intelligence start-up InstaDeep for up to £562 million as the German business diversifies beyond the Covid-19 vaccine that has completely changed its fortunes.
The biotech startup is attempting to use machine learning to accelerate the drug development process and provide customised therapies based on a patient’s cancer. The agreement followed a lengthy partnership with London-based InstaDeep that produced an early warning system to foretell new Sars CoV-2 virus strains. Last year, BioNTech contributed to InstaDeep’s £100 million investment round.
Using “computational solutions,” according to BioNTech’s chief executive Uur Ahin, the German pharmaceutical company has concentrated on developing customised medications known as immunotherapies since its founding.With the purchase of InstaDeep, he added, “we are now able to integrate the fast
Continue with Facebook Continue with Google